MARKET

ACTU

ACTU

Actuate Therapeutics Inc
NASDAQ
1.020
-0.085
-7.69%
After Hours: 1.020 0 0.00% 16:10 08/10 EDT
OPEN
1.130
PREV CLOSE
1.105
HIGH
1.140
LOW
1.000
VOLUME
215.25K
TURNOVER
--
52 WEEK HIGH
9.22
52 WEEK LOW
1.000
MARKET CAP
24.40M
P/E (TTM)
-1.0323
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACTU last week (0803-0807)?
Weekly Report · 10h ago
Weekly Report: what happened at ACTU last week (0727-0731)?
Weekly Report · 08/03 09:23
This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Benzinga · 07/30 15:41
Actuate Therapeutics Initiated at Buy by Rodman & Renshaw
Dow Jones · 07/30 12:29
Actuate Therapeutics Price Target Announced at $6.00/Share by Rodman & Renshaw
Dow Jones · 07/30 12:29
Rodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6
Benzinga · 07/30 12:21
Weekly Report: what happened at ACTU last week (0720-0724)?
Weekly Report · 07/27 09:24
Weekly Report: what happened at ACTU last week (0713-0717)?
Weekly Report · 07/20 09:23
More
About ACTU
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Webull offers Actuate Therapeutics Inc stock information, including NASDAQ: ACTU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACTU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACTU stock methods without spending real money on the virtual paper trading platform.